MA46437A - Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci. - Google Patents

Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci.

Info

Publication number
MA46437A
MA46437A MA046437A MA46437A MA46437A MA 46437 A MA46437 A MA 46437A MA 046437 A MA046437 A MA 046437A MA 46437 A MA46437 A MA 46437A MA 46437 A MA46437 A MA 46437A
Authority
MA
Morocco
Prior art keywords
compounds
methods
pharmaceutical compositions
ppar agonists
ppar
Prior art date
Application number
MA046437A
Other languages
English (en)
Other versions
MA46437B1 (fr
Inventor
Michael Downes
Ronald M Evans
Arthur Kluge
Bharat Lagu
Masanori Miura
Sunil Kumar Panigrahi
Michael Patane
Susanta Samajdar
Ramesh Senaiar
Taisuke Takahashi
Original Assignee
Mitobridge Inc
Salk Inst Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc, Salk Inst Biological Studies filed Critical Mitobridge Inc
Priority claimed from PCT/US2016/055521 external-priority patent/WO2017062468A1/fr
Publication of MA46437A publication Critical patent/MA46437A/fr
Publication of MA46437B1 publication Critical patent/MA46437B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA46437A 2015-10-07 2016-10-05 Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci. MA46437B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
PCT/US2016/055521 WO2017062468A1 (fr) 2015-10-07 2016-10-05 Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
MA46437A true MA46437A (fr) 2021-04-21
MA46437B1 MA46437B1 (fr) 2022-03-31

Family

ID=61158553

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46437A MA46437B1 (fr) 2015-10-07 2016-10-05 Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci.

Country Status (2)

Country Link
AR (1) AR106298A1 (fr)
MA (1) MA46437B1 (fr)

Also Published As

Publication number Publication date
MA46437B1 (fr) 2022-03-31
AR106298A1 (es) 2018-01-03

Similar Documents

Publication Publication Date Title
MA52098A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EP3665156A4 (fr) Composés, compositions et procédés
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
EP3676297A4 (fr) Composés, compositions et procédés
EP3316894A4 (fr) Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3340988A4 (fr) Composés inhibiteurs de canaux ioniques, formulations pharmaceutiques, et utilisations
EP3364984A4 (fr) Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3845528A4 (fr) Composés de pyrazole, compositions pharmaceutiques correspondantes et utilisation associées
EP3496768A4 (fr) Compositions antimicrobiennes et procédés d'utilisation associés.
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
EP3383853A4 (fr) Dérivés d'homobispypéridinyle en tant qu'agonistes des oxystérols bêta, compositions et leur utilisation
MA46543A (fr) Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
EP3334719A4 (fr) Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
EP3468555A4 (fr) Composés antimicrobiens et leurs procédés d'utilisation
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
EP3347003A4 (fr) Composés de thréonate et leurs procédés d'utilisation
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
EP3717475A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3280271A4 (fr) Compositions d'aliment pour animaux et procédés d'utilisation